Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript
Operator: Good morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 930,000 | $6,844,800 | 0.9% | |
| 2. | Ikarian Capital Neil Shahrestani | 544,554 | $4,007,918 | +1898% | 0.31% |
| 3. | Soleus Capital Guy Levy | 440,000 | $3,238,400 | 0.12% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 421,322 | $3,100,930 | 0% | |
| 5. | Davidson Kempner Thomas Lenox Kempner | 310,020 | $2,281,747 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.22 | 41,140 | $49,985.10 | 45,140 | 2023-09-12 | Filing | |
| $8.60 | 23,250 | $199,991.85 | 131,802 | 2021-05-07 | Filing | |
| $7.82 | 4,000 | $31,280.00 | 4,000 | 2021-05-06 | Filing | |
| $14.54 | 7,500 | $109,012.50 | 7,500 | 2020-08-26 | Filing | |
| $33.00 | 2,000 | $66,000.00 | 3,000 | 2015-04-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.63 | 378 | $3,262.14 | 99,429 | 2026-02-17 | Filing | |
| $6.30 | 1,626 | $10,243.80 | 85,105 | 2026-02-03 | Filing | |
| $7.03 | 50 | $351.50 | 22,622 | 2026-01-28 | Filing | |
| $5.96 | 265 | $1,579.40 | 22,580 | 2026-01-21 | Filing | |
| $6.30 | 362 | $2,279.15 | 10,046 | 2025-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 889,575 | $6,547,272 | 0.37% | |
| 2. | 559,619 | $4,118,796 | 0% | |
| 3. | 366,300 | $2,695,968 | 0% | |
| 4. | 320,900 | $2,361,824 | 0% | |
| 5. | 276,881 | $2,037,844 | 0% |
News See All
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript November 3, 2025Karyopharm Therapeutics Inc. misses on earnings expectations.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript August 11, 2025Karyopharm Therapeutics Inc. misses on earnings expectations.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Chloe, and I will be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript
Operator: Good morning. My name is Jewel, and I will be your conference operator today.
12 Best Penny Stocks to Invest in According to the Media
On December 24, Global Advisors’ managing partner, Tom Lee, shared his thoughts on the potential of small and mid-cap stocks in 2025.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Jenny, and I will be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
Operator: Good morning. My name is Liz [ph] and I'll be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Hedge Fund Resource Center